Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.
Qingnan ZhaoJiemiao HuAbhisek MitraJeffry CutreraWendong ZhangZhongting ZhangJun YanXueqing XiaKris Michael MahadeoJohn Andrew LivingstonRichard GorlickShulin LiPublished in: Journal for immunotherapy of cancer (2019)
ttIL-12 when combined with surgery led to conversion to the IFNγHiCD8HiFOXP3LowCD33Low immune profile, eliminated relapse and metastasis, and prolonged overall survival.